Literature DB >> 22234794

Acute perfusion changes after spontaneous SAH: a perfusion CT study.

Alfonso Lagares1, Marta Cicuendez, Ana Ramos, Elena Salvador, Jose F Alén, Ariel Kaen, Luis Jiménez-Roldán, J M Millán.   

Abstract

BACKGROUND: Perfusion computed tomography (CT) is a rapid technique that allows the measurement of acute disturbances in local and global cerebral blood flow in patients suffering stroke and spontaneous subarachnoid haemorrhage (SAH). The purpose of this study was to establish the relationship between different measures of brain perfusion made on dynamic-contrast CT reconstructions performed as soon as SAH has been diagnosed and the severity of the bleeding determined by the clinical grade, the extent of the bleeding and the outcome of the patients.
METHODS: After the diagnosis of SAH by conventional CT, a perfusion CT was performed before CT angiography. All imaging studies were performed on a six-slice spiral CT scanner. All images were analysed using perfusion software developed by Philips, which produces perfusion CT quantitative data based on temporal changes in signal intensity during the first pass of a bolus of an iodinated contrast agent. Measurements of mean transient time (MTT), time to peak (TTP), cerebral blood volume (CBV) and cerebral blood flow (CBF) in volumes of interest corresponding to territories perfused by the major cerebral arteries were performed. Different data regarding severity of the bleeding-such as level of consciousness, amount of bleeding in conventional CT-were collected. All poor-grade patients received a ventriculostomy catheter so that ICP recordings were obtained. Also, the occurrence of delayed cerebral ischaemia (DCI) was recorded. Outcome was assessed by the Glasgow Outcome Scale 6 months after the bleeding. For statistical analysis, non-parametric correlations between variables were performed.
FINDINGS: Thirty-nine patients have been included in the study since January 2007. In SAH patients there are increasing perfusion abnormalities as the severity of the bleeding increases. The most affected perfusion parameters are TTP and MTT, as they significantly increase with the clinical severity of the bleeding and the total volume of bleeding (P < 0.01, Spearman's Rho). When average MTT time is increased over 5.9 s there is a 20-fold (95% CI = 2.1-182) risk of poor outcome. All patients presenting this MTT time suffered from DCI. This value has a positive predictive value of 100% for DCI and 90% for a poor outcome.
CONCLUSIONS: SAH causes cerebral blood flow abnormalities even in the acute phase of the illness, consisting mainly of an increase in circulation times (TTP and MTT), which are correlated with the severity of the bleeding.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22234794     DOI: 10.1007/s00701-011-1267-z

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  13 in total

1.  Early CT perfusion changes and blood-brain barrier permeability after aneurysmal subarachnoid hemorrhage.

Authors:  Amanda Murphy; Airton Leonardo de Oliveira Manoel; Kyle Burgers; Ekaterina Kouzmina; Ting Lee; R Loch Macdonald; Aditya Bharatha
Journal:  Neuroradiology       Date:  2015-04-14       Impact factor: 2.804

2.  Computed tomography perfusion as a predictor of delayed cerebral ischemia and functional outcome in spontaneous subarachnoid hemorrhage: A single center experience.

Authors:  Isabel Fragata; Marta Alves; Ana Luísa Papoila; Ana Paiva Nunes; Patrícia Ferreira; Mariana Diogo; Nuno Canto-Moreira; Patrícia Canhão
Journal:  Neuroradiol J       Date:  2019-02-19

3.  Comparison of cerebral perfusion in perimesencephalic subarachnoid hemorrhage and aneurysmal subarachnoid hemorrhage.

Authors:  Isabel Fragata; Nuno Canto-Moreira; Patrícia Canhão
Journal:  Neuroradiology       Date:  2018-03-09       Impact factor: 2.804

4.  Effect of APOE Gene Polymorphism on Early Cerebral Perfusion After Aneurysmal Subarachnoid Hemorrhage.

Authors:  Chongjie Cheng; Li Jiang; Yanhong Yang; Haitao Wu; Zhijian Huang; Xiaochuan Sun
Journal:  Transl Stroke Res       Date:  2015-09-14       Impact factor: 6.829

5.  Role of microcirculatory impairment in delayed cerebral ischemia and outcome after aneurysmal subarachnoid hemorrhage.

Authors:  Masato Naraoka; Naoya Matsuda; Norihito Shimamura; Hiroki Ohkuma
Journal:  J Cereb Blood Flow Metab       Date:  2021-09-09       Impact factor: 6.960

Review 6.  CT perfusion and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.

Authors:  Charlotte H P Cremers; Irene C van der Schaaf; Emerens Wensink; Jacoba P Greving; Gabriel J E Rinkel; Birgitta K Velthuis; Mervyn D I Vergouwen
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-27       Impact factor: 6.200

7.  Default Mode Network Perfusion in Aneurysmal Subarachnoid Hemorrhage.

Authors:  Sarah Nelson; Brian L Edlow; Ona Wu; Eric S Rosenthal; M Brandon Westover; Guy Rordorf
Journal:  Neurocrit Care       Date:  2016-10       Impact factor: 3.210

8.  Prospective Multicenter Study of Changes in MTT after Aneurysmal SAH and Relationship to Delayed Cerebral Ischemia in Patients with Good- and Poor-Grade Admission Status.

Authors:  A Murphy; T-Y Lee; T R Marotta; J Spears; R L Macdonald; R I Aviv; A Baker; A Bharatha
Journal:  AJNR Am J Neuroradiol       Date:  2018-10-18       Impact factor: 3.825

Review 9.  CT perfusion for detection of delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.

Authors:  D I A Mir; A Gupta; A Dunning; L Puchi; C L Robinson; H-A B Epstein; P C Sanelli
Journal:  AJNR Am J Neuroradiol       Date:  2013-12-05       Impact factor: 3.825

10.  Evaluating CT perfusion using outcome measures of delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage.

Authors:  P C Sanelli; N Anumula; C E Johnson; J P Comunale; A J Tsiouris; H Riina; A Z Segal; P E Stieg; R D Zimmerman; A I Mushlin
Journal:  AJNR Am J Neuroradiol       Date:  2012-08-02       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.